HEPATOSELLÜLER KARSINOM, KOLANJIOSELLÜLER KARSINOM VE KOLON ADENOKARSINOM METASTAZLARININ AYIRICI TANISINDA İMMUNOHISTOKIMYASAL METODLAR

Öz

Giriş: Karaciğer insan vücüdunda metabolizma fonksiyonlarının yürütüldüğü temel organdır. Kanserleri dünyada kanserden ölüm sebebleri arasında 3.sırada yer alır. Metastazları en sık görülen malign tümörleridir. Primer malign tümörlerinden hepatosellüler karsinom (%80-90) ikinci sıklıkta,kolanjiokarsinom da 3. sıklıkta görülen malign tümörleridir (%10-15). Bu tümörlerin erken tanı alması, tedavinin erken planlanması açısından önemlidir. Geç evre hepatosellüler karsinom kolay tespit edilebilmesine rağmen büyük oranda tedavi edilememekte ve nüks izlenmektedir. Bundan dolayı ayırıcı tanıda daha sensitif ve spesifik antikorlar kullanarak, rutin uygulamada kullanılmakta olan diğer belirleyicilerin etkinliğini artırmak, daha erken tanıya ulaşmak gerekmektedir. Metot: Çalışmamızda 60 adet olguya ait biyopsi ve rezeksiyon materyallerinin parafin bloklarında immunohistokimyasal olarak Glypican-3, Agrin/CD34 kombinasyonu, CDX2 çalışıldı. Bulgular: Daha önce çalışılmış HepPar1, AFP, CEA, CD10, CK-19, CK-7, CK-20, CK-8, CK-18 ile kombine değerlendirildiğinde özellikle GPC-3’ün hepatosellüler karsinomda HepPar1 ve AFP’ye göre daha sensitif ve spesifik olduğu gözlendi. Ayrıca kolanjiosellüler karsinom ve kolon adenokarsinom metastatik tümörlerleriyle ayırıcı tanısında oldukça faydalı olduğu tespit edildi. Agrin’in hepatosellüler karsinomlu dokularda yeni damarlanma alanlarında izlenmesine rağmen kolanjiosellüler karsinom ve kolon adenokarsinom metastazlı dokularda izlenmemesi dikkatimizi çekti. CDX2 ile kolon adenokarsinom metastazlı dokularda boyanma gözlenirken, hepatosellüler karsinom ve kolanjiosellüler karsinomda çok az boyanma izlenmesi de ayırıcı tanıda önemli bir bulguydu. Sonuç: Bulgularımızın hepsini bir arada değerlendirdiğimizde, GPC-3, Agrin ve CDX2 oldukça sensitif ve spesifik belirleyicilerdir. Olguların erken tanılanmasını ve daha hızlı tedavi almasını sağlayıp, hastaların surveyini uzatması açısından rutinde de uygulanması gerekir.

Anahtar Kelimeler

• Hepatosellüler Karsinom
• Kolanjiosellüler Karsinom
• Kolon Adenokarsinom Metastazı
• İmmunohistokimya
• Glypican-3
• Agrin
• CDX2

NEW IMMUNOHİSTOCHEMİCAL METHODS IN THE DİFFERENTIAL DIAGNOSİS OF HEPATOCELLULAR CARCİNOMA, CHOLANGIOCELLULAR CARCİNOMA, AND COLON ADENOCARCINOMA METASTASES

Öz

Objectives: Liver is the main organ carrying out metabolic functions in the human body. The cause of death from cancer is the third among cancers in the world. Metastases are the most common malignant tumors in liver. Hepatocellular carcinoma, primary malignant tumors of the liver, is the second (80-90 %), and cholangiocellular carcinoma is the third (10-15 %) most common malignant tumor of liver. Early diagnosis in these tumors is important for early treatment planning. Although late-stage hepatocellular carcinoma is easily detectable, the treatment could not be avaliable in a large proportion and recurrence is frequently observed. Therefore, in the differential diagnosis using more sensitive and specific antibodies can increase the effectiveness of the other markers used in routine practice, and can achieve an earlier diagnosis. Methods: In our study, paraffin blocks of the biopsy and resection material of 60 cases were studied immunohistochemically with GPC-3, Agrin/CD34 combination, CDX2. Results: HepPar1, AFP, CEA, CD10, CK-19, CK-7, CK-20, CK-8 and CK-18 which are studied previously, were evaluated in combination with GPC-3 in hepatocellular carcinoma, and GPC-3 was found to be more sensitive and specific than HepPar1 and AFP. In the differential diagnosis of hepatocellular carcinoma from cholangiocellular carcinoma and metastatic adenocarcinoma of the colon, GPC-3 was also found to be very useful. Although in hepatocellular carcinoma tissues Agrin was observed in the new areas of vascularity, it was not observed in the areas of cholangiocellular carcinoma and tissues of metastatic colon adenocarcinoma. That has been followed in our attention. CDX2 staining was observed in tissues with metastatic adenocarcinoma of the colon, but it is very little in hepatocellular carcinoma and cholangiocellular carcinoma. This is an important finding in the differential diagnosis. Conclusion: Considered a combination of all of our findings, Glypican-3, Agrin/CD34 combination and CDX2 are very sensitive and specific markers of hepatocellular carcinoma. These markers must be applied in routine practice for early diagnosis and treatment, and for the extend of the survey in patients with hepatocellular carcinoma.

Anahtar Kelimeler

• Hepatocellular Carcinoma
• Cholangiocellular Carcinoma
• Metastatic Adenocarcinoma of the Colon
• Immunohistochemistry
• Glypican-3
• Agrin/CD34 combination
• CDX2

Kaynakça

1. Referans1- Carol Man Tong, Stephianie Ma and Xin-Yuan Guan, Biology of Hepatic Cancer Stem Cells. Journal of Gastroenterology and Hepatology. 2011;1440-1746.
2. Referans2- Asmaa Ibrahim Gomaa, shahid A Khan, Mireille B Toledano,Imam Waked,simon D Taylor-Robinson. Hepatocellular carcinoma : Epidemiology , risk factors and pathogenesis. World Journal Gastroenterology 2008 ;14:4300-4308.
3. Referans3- J Schölmerich, D Schacherer.Diagnostic biopsy for hepatocellular carcinoma in cirrhosis: useful,necessary,dangerous,or academic sport? Gut 2004;53: 1224-1226.
4. Referans4- Kay Washington. liver neoplasms In: Christine A.lacobuzio-Donahue Elizabeth A.Montgomery,Gastrointestinal and LiverPathology 1st ed. Churchill Livingstone Elsevier:2005;p582-632.
5. Referans5- Linda D. Ferrel,Kim R. Geisinger.Surgical Diseases of the Liver In:Silverberg SG,DeLellis RA et al(eds).Silverberg’s Principles and Cytopathology.4th ed.Churchill Livingstone Elsevier.2006;p1530-1536.
6. Referans6- Jakubovic BD, Jothy S. Glypican-3: From the mutations of Simpson-Golabi-Behmel genetic syndrome to a tumor marker for hepatocellular carcinoma. Experimental and Molecular Pathology 2007; 184-189.
7. Referans7- Filmus J,Glypicans in growth control and cancer.2001;11:19R-23R.Review
8. Referans8- Pilia G, Hughes-Benzie RM, MacKenzie A, Baybayan P, Chen EY, Huber R, Neri G, Cao A, Forabosco A, Schlessinger D.Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth

9. Referans9- Gonzalez AD, Kaya M, Shi W, Song H, Testa JR, Penn LZ, Filmus J OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner. The Journal of Cell Biology. 1998 ;141:1407-14.
10. Referans10- Xiang YY, Ladeda V, Filmus J. Glypican-3 expression is silenced in human breast cancer. Oncogene. 2001;20:7408-12.
11. Referans11- Man XB, Tang L, Zhang BH, Li SJ, Qiu XH, Wu MC, Wang HY. Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers. Liver International. 2005 ; 25:962-6.9- Rosenberg AE., Roth S.I.:Bone In:Mills S.E.Histology for Pathologists.third edition. Lippincott Williams& Wilkins.2007:p686-697.
12. Referans12- Coggin JH. The implications of embriyonic gene expression in neoplasia.CRC Crit. rev.Onco./Hemat. 1992;5: 37-55.
13. Referans13- Matsuura H, Takio K, Titani K, Greene T, Levery SB, Salyan ME, Hakomori S. The oncofetal structure of human fibronectin defined by monoclonal antibody FDC-6. Unique structural requirement for the antigenic specificity provided by a glycosylhexapeptide. The Jornal of Biological Chemistry. 1988;263:3314-22.
14. Referans14- Hsu HC, Cheng W, Lai PL. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Research. 1997;57:5179-84.15- Cho KJ, Lunderquist A. The peribiliary vascular plexus: the micravascular architecture of the bile duct in the rabbit and in clinical cases. Radiology. 1983;147:35764.
15. Referans15- Washington K. Liver Neoplasms In:Lacobuzio-Donahue CA, Montgomery EA. Gastrointestinal and Liver Pathology. 1th ed. Churchill Livingstone Elsevier, 2005:582-632.
16. Referans16-Anatelli F, Chuang ST, Yang XJ, Wang HL. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. Am J Clin Pathol 2008; 130: 219–23–8.
17. Referans17- Asmaa I Gomaa, Shahid A Khan, Edward LS Leen, Imam Waked,simon D Taylor-Robinson.Diagnosis of hepatocellular carcinoma.World Journal of Gastroenterology 2009;15:1301-1314.
18. Referans18- Peter Tatrai, Jozsef Dudas, Enkhjargal Batmunkh, Miklos Mathe and et all. Agrin, a novel basement membrane component in human and rat liver, accumulates in cirrhosis and hepatocellular carcinoma. Laboratory İnvestigation 2006;86: 1149-1160.
19. Referans19- Peter Tatrai. Selective deposition of agrin in the microvascularite of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis. Semmelweis University Doctoral School of Pathology, Doctoral (Ph. D.) theses, Budapest, 2008.
20. Referans20- Peter Tatrai, Somoracz A, Batmunkh E and et all. Agrin and CD34 immunohistochemistry for the discrimination of benign versus malignant hepatocellular lesions. Am J Surg Pathol. 2009 ;33:874-85.
21. Referans21- Ho SB, Shekels LL, Toribana NW, Kim YS, Lyftogt C, Cherwitz DL et al. Mucin gene expression in normal, preneoplastic and neoplastic human gastric epithelium. Cancer Rec 1995; 55:2681-90.
22. Referans22-Batmunkh E, Tatrai P,Szabo E and et all. Comparison of the expression of agrin, a basement membrane heparin sulfate proteoglycan,in cholangiocarcinoma and hepatocellular carcinoma. Hum Pathology. 2007 ;38:1508.
23. Referans23- James R,Erler T,Kazenwadel J.Structure of the murine homeobox gene cdx-2. Expression in embryonic and adult intestinal epithelium. J Biol Chem 1994; 269:15229-37.
24. Referans24- Suh E,Traber PG. An intestine-specific homeobox gene regulates proliferation and differentiation. Mol Cel 56- McGinnis W, Krumlauf R. Homeobox genes and axial patterning. Cell 1992; 68:283-302.
25. Referans25- McGinnis W, Krumlauf R. Homeobox genes and axial patterning. Cell 1992; 68:283-302.
26. Referans26- Freund JN, Domon-Dell C,Kedinger M,Duluc I. The Cdx-1 and Cdx-2 homeobox genes in the intestine. Biochem Cell Biol 1998;76: 957.
27. Referans27- Mallo GV, Rechreche H, Frigerio JM, Rocha D, Zweibaum A, Lacasa M, Jordan BR, Dusetti NJ, Dagorn JC, Iovanna JL. Molecular cloning, sequencing and expression of the mRNA encoding human Cdx1 and Cdx2 homeobox. Down-regulation of Cdx1 and Cdx2 mRNA expression during colorectal carcinogenesis. Int J Cancer. 1997;74:3544.
28. Referans28- Mallo GV, Soubeyran PLissitzky JC,Andre F,Farnarier C,Marvaldi J,Dagorn JC,Iovanna JL.Expression of the Cdx1 and Cdx2 homeotic genes leads to reduced malignancy in colon cancer-derived cells. J Biol Chem. 1998; 273:14030-6.
29. Referans29- Sivagnanasundaram S,Islam I,Talbot I,Drummond F,Walters JR, Edwards YHThe homeobox gene CDX2 in colorectal carcinoma: a genetic analysis. Br J Cancer. 2001;84:218-25.
30. Referans30- Yagi OK, Akiyama Y,Yuasa Y.Genomic structure and alterations of homeobox gene CDX2 in colorectal carcinomas. Br J Cancer. 1999;7:440-4.
31. Referans31- Barbareschi M,Roldo C,Zamboni G,Capelli P,Cavazza A, Macri E, Cangi MG, Chilosi M,Doglioni C. CDX-2 homeobox gene product expression in neuroendocrine tumors: its role as a marker of intestinal neuroendocrine tumors. Am J Surg Pathol.2004;28:1169-76.
32. Referans32- Stanley R. Hamilton, Lauri A. Aaltonen. :World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. Lyon France IARC Press 2000;158-202.
33. Referans33- Rosenberg AE., Roth S.I.:Bone In:Mills S.E.Histology for Pathologists.third edition. Lippincott Williams& Wilkins.2007:p686-697.
34. Referans34- Mitchell Ho and Heungnam Kim, Glypican-3: a nem target for cancer immunotherapy. Eur J Cancer. 2011; 47: 333-338.
35. Referans35-Daniel Baumhoer, Luigi Tornillo, Sylvia Stadlmann, Massimo Roncalli, Eva Karamitopoulou Diamantis, and Luigi M. Terracciano, Glyypican 3 Expression in Human Nonneoplastic, Preneoplastic, and Neoplastic Tissues. Am J Clin Pathol 2008;129:899-906.
36. Referans36- Naoko Yamauchi, Akira Watanabe, Michiyo Hishunuma and et all. The glypican3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Modern Pathology 2005;18:1591-1598.
37. Referans37- Saverio Ligato, Daniza Mandich and Richard W Cartun, Utility of glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: an immunocytochemical study. Modern Pathology 2008; 21:626-631.
38. Referans38- Nafis Shafizade, Linda D Ferrell and Sanjay Kakar, Utility and limitations of glypican-3 expression fort he diagnosis of hepatocellular carcinoma at both ende of the differentiation spectrum. Modern Pathology 2008;21:1011-1018.
39. Referans39- Dina Kandil, Gladwyn Leiman, Mark Allegretta,Winifred Trotman,Liron Pantanowitz,Robert Goulart,Mark Evans,Glypican-3 Immunocytochemistry in Liver Fine-needle Aspirates.Cancer Cytopathology 2007; Volume 111,Number 5.
40. Referans40- Christopher A. Moskaluk, Hong Zhang, Steven M. Powell, Lisa A. Cerilli, Garret M. Hampton, Henry F. Frierson, Jr. Cdx2 Protein Expression in Normal and Malignant Human Tissues: An Immunohistochemical Survey Using Tissue Microarrays. Mod Pathol 2003;16:913-919.
41. Referans41- Alexandre Sherlley Casimiro Onofre, Natalia Pomjanski, Birgit Buckstegge, Alfred Böcking, Immunocytochemical Diagnosis of Hepatocellular Carcinoma and Identification of Carcinomas of Unknown Primary Metastatic to the Liver on Fine-Needle Aspiration Cytologies. Cancer Cytopathology 2007/Volume 111/ Number 4.
42. Referans42- Jinawath A, Akiyama Y, Yuasa Y, Pairojkul C, Expression of phosphorylated ERK1/2 and homeodomain protein CDX2 in cholangiocarcinoma. J.Cancer Res Clin Oncol 2006; 132;805-10.